Link between prostate cancer and vitamin A may lead to improved treatment

September 5, 2012

(Medical Xpress)—Cancer scientists at the University of York have shown a link between prostate cancer and vitamin A for the first time.

Professor Norman Maitland, who was awarded £2.15m by Yorkshire Cancer Research a year ago to continue his groundbreaking research into , has found that a prostate specific gene is under the control of retinoic acid – a derivative of vitamin A.

The discovery, which is published in the scientific journal , means that it will now be possible to test whether retinoic acid, if given therapeutically, can force prostate cancer stem cells to develop into more – a process known as differentiation - which could kill them or render them more susceptible to chemotherapy.

All-trans retinoic acid therapy (ATRA) is already used in another cancer – acute promyelomcytic leukaemia (APL) – and has been hugely successful in improving from 0% to 80%.

Nearly 41,000 men are diagnosed with prostate cancer every year in the UK, and although around 80% survive for five years or more, 10,000 men die annually.

Professor Maitland, Director of the YCR Cancer Research Unit in the Department of Biology, said: "It has been known for many years that low vitamin A in samples of blood is associated with prostate cancer, but nobody knew the mechanisms involved. We have revealed a functional biological link between retinoic and our laboratory models of prostate cancers.

"Specifically, the gene we have investigated – the prostate transglutaminase (TGP) – is one of the most prostate-specific genes known from the 28,000 in the . We have shown that the TGP gene is controlled by the retinoic acid signalling pathway.

"When retinoic acid gets into a prostate cancer cell, it binds to one of three receptors in the nucleus of the cell. This binding then triggers a sequence of molecular events inside the nucleus which results in the TGP gene being turned on or off. We have shown that the same situation also applies to a number of other genes. All of these genes then tell the cell how to behave – to divide for example."

In a separate review article published in Nature Reviews Urology, Professor Maitland argues that differentiation therapies have previously been misused in cancer treatments, but that used in lower doses, they could be a realistic treatment option.

He said: "Onocologists have been using agents such as retinoic acid as toxins. What we need to do is use them at lower doses so that they change the properties of the susceptible cells. However, they may affect normal and some cells may react unpredictably, so we need to investigate what happens before we try the treatment on patients. This will now form part of our experimental approach in York."

Explore further: BRG1 mutations confer resistance to hormones in lung cancer

Related Stories

BRG1 mutations confer resistance to hormones in lung cancer

March 15, 2012
Retinoic acid (vitamin A) and steroids are hormones found in our body that protect against oxidative stress, reduce inflammation and are involved in cellular differentiation processes. One of the characteristics of tumours ...

Prostate cancer early warning protein detected

May 31, 2012
(Medical Xpress) -- Scientists at the University have discovered a protein, only present in prostate cancer cells, that could be used as a marker to detect early signs of the disease.     

Scientists identify new mechanism of prostate cancer cell metabolism

March 22, 2012
Cancer cell metabolism may present a new target for therapy as scientists have uncovered a possible gene that leads to greater growth of prostate cancer cells.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.